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SUMMARY 
 Glycogen is the major mammalian glucose storage cache and is critical for energy 
homeostasis. Glycogen synthesis in neurons must be tightly controlled, due to neuronal 
sensitivity to perturbations in glycogen metabolism. Lafora disease (LD) is a fatal, congenital, 
neurodegenerative epilepsy. Mutations in the gene encoding the glycogen phosphatase laforin 
result in hyperphosphorylated glycogen that forms water-insoluble inclusions called Lafora 
bodies (LBs). LBs induce neuronal apoptosis and are the causative agent of LD. The 
mechanism of glycogen dephosphorylation by laforin and dysfunction in LD is unknown. We 
report the crystal structure of laforin bound to phosphoglucan product, revealing its unique 
integrated tertiary and quaternary structure. Structure-guided mutagenesis combined with 
biophysical and biochemical analyses reveal the basis for normal function of laforin in glycogen 
metabolism. Analyses of LD patient mutations define the mechanism by which subsets of 
mutations disrupt laforin function. These data provide fundamental insights connecting glycogen 
metabolism to neurodegenerative disease.   
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INTRODUCTION 
Glycogen, the major glucose storage molecule in animals, plays an essential role in energy 
metabolism throughout the body. The brain is the organ most susceptible to decreases in 
glucose availability (Dinuzzo et al., 2014; Fryer and Brown, 2014). During the past 20 years, the 
perceived role of brain glycogen has shifted from an emergency energy supply to a dynamic 
participant in brain metabolism (Dinuzzo et al., 2014; Fryer and Brown, 2014; Swanson, 1992). 
While neuronal glycogen was thought to be limited to embryonic neurons, adult neurons 
express both glycogen synthase and glycogen phosphorylase, and they produce low levels of 
glycogen (Duran et al., 2014; Lovatt et al., 2007; Pfeiffer-Guglielmi et al., 2003; Saez et al., 
2014; Vilchez et al., 2007). However, glycogen synthesis in neurons must be tightly controlled, 
because both over-accumulation and aberrant accumulation induce neuronal apoptosis 
(DePaoli-Roach et al., 2010; Duran et al., 2014; Turnbull et al., 2011; Valles-Ortega et al., 2011; 
Vilchez et al., 2007).  
Glycogen is a branched polymer of glucose units joined by α-1,4-glycosidic linkages, formed 
by glycogen synthase, and branches occurring every 12-14 units via α-1,6-glycosidic branches, 
created by branching enzyme (Roach et al., 2012). Branches within glycogen are evenly 
distributed, resulting in a spherical structure with exposed non-reducing chain ends. This unique 
organization allows cells to store up to ≈55,000 glucose units in a water-soluble form that can be 
rapidly released during bursts of metabolic energetics. Mutations in the Epilepsy, Progressive 
Myoclonus 2A (EPM2A) gene encoding the glycogen phosphatase laforin cause Lafora disease 
(LD) (Minassian et al., 1998; Serratosa et al., 1999). Laforin mutations result in 
hyperphosphorylated glycogen with decreased branching and increased glucose chain length 
that eventually forms an insoluble glucan inclusion called a Lafora body (LB) (Nitschke et al., 
2013; Tagliabracci et al., 2011). Notably, it was recognized that LBs share a similar morphology 
with plant amylopectin, the major constituent of starch (Yokoi et al., 1968). Starch also contains 
branched polymers of glucose, but it is water-insoluble due to its longer glucose chains of 20-25 
glucose units that are branched in clusters and form helices that exclude water (Blennow and 
Engelsen, 2010; Gallant et al., 1997). Recent studies demonstrated that LBs possess longer 
glucose chains than glycogen and they contain monoester-bound phosphate, both molecular 
features that resemble plant starch rather than human glycogen (Nitschke et al., 2013; 
Tagliabracci et al., 2011). Indeed, LD is one of a family of glycogen storage diseases and offers 
a unique window into glycogen metabolism and associated diseases.  
LD is a fatal, autosomal recessive, neurodegenerative disorder and one of the five major 
progressive myoclonic epilepsies (Berkovic et al., 1991; Minassian et al., 2001). LD patients 
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typically present with an epileptic event in the second decade of life that invariably progresses to 
intractable and fatal seizures within 5-10 years (Berkovic et al., 1991; Minassian et al., 2001). 
Disease symptoms result from neuronal apoptosis driven by the accumulation of the 
cytoplasmic, hyperphosphorylated, water-insoluble LB inclusions, which are normally prevented 
by the action of laforin (Duran et al., 2014; Turnbull et al., 2011; Valles-Ortega et al., 2011; 
Vilchez et al., 2007). These inclusions occur throughout the body, but neurons are acutely 
sensitive to polyglucosan-mediated toxicity (DePaoli-Roach et al., 2010; Duran et al., 2014; 
Valles-Ortega et al., 2011; Vilchez et al., 2007).  
 Laforin is the founding member of the glucan phosphatase family and dephosphorylates 
glycogen both in vitro and in vivo (Gentry et al., 2007; Tagliabracci et al., 2008; Tagliabracci et 
al., 2007; Worby et al., 2006). Laforin possesses a carbohydrate binding module (CBM) family 
20 domain followed by a dual specificity phosphatase (DSP) domain (Minassian et al., 1998; 
Serratosa et al., 1999; Wang et al., 2002). Highlighting its basic biological importance, laforin 
orthologs are found in all vertebrates as well as several unicellular eukaryotes (Gentry et al., 
2007; Gentry and Pace, 2009). While having a critical role in normal glycogen metabolism and 
aberrant LB formation, the mechanism of glycogen dephosphorylation by laforin is not known. 
Further, LD mutations are distributed throughout the primary sequence of laforin, leaving open 
the critical question of the mechanism(s) by which mutations in laforin lead to LB formation. 
 Plants utilize a cyclic process of reversible phosphorylation by glucan dikinases and glucan 
phosphatases for efficient starch degradation (Silver et al., 2014; Streb and Zeeman, 2012). 
Phosphorylation of starch outer glucans results in solubilization, thereby allowing degradation by 
starch hydrolyzing amylases, and subsequent dephosphorylation by the glucan phosphatases 
Starch EXcess 4 (SEX4) and Like Sex Four2 (LSF2). All known glucan phosphatases are 
members of the Protein Tyrosine Phosphatase (PTP) superfamily within the Dual-Specificity 
Phosphatases (DSPs) clade (Gentry et al., 2009; Gentry et al., 2007; Tonks, 2006). The DSP 
domain is an ~150 amino acid domain that is <10% identical among the 65 human DSPs. The 
heterogeneous DSPs all utilize a cysteine residue at the base of the active site within the 
conserved Cx5R catalytic motif to perform nucleophilic attack on the phosphorus atom of the 
substrate (Tonks, 2006). Differences within the DSP domain and active site allow for different 
members of the DSP family to specifically dephosphorylate proteinaceous substrates, glucans, 
lipids, or nucleic acids (Moorhead et al., 2009; Tonks, 2006).  
 Each glucan phosphatase possesses unique features that enable it to bind and 
dephosphorylate phosphorylated glucans. We recently demonstrated the molecular basis for 
plant glucan phosphatase function (Meekins et al., 2013; Meekins et al., 2014; Vander Kooi et 
	   5	  
al., 2010). SEX4 possesses a DSP and CBM domain followed by a carboxy-terminal (CT)-motif. 
In SEX4, the DSP and CBM share an extensive interdomain interface that forms a continuous 
binding pocket to engage a hexasaccharide. Conversely, LSF2 possesses only a DSP domain 
and CT-motif and utilizes two Secondary Binding Sites (SBSs) to engage glucan substrates. 
Laforin possesses CBM and DSP domains in the reverse orientation as SEX4, it lacks a CT 
motif, and it possesses a unique inter-domain linker suggesting a novel physical basis for the 
specific activity of laforin versus glycogen.  
Despite glycogen metabolism being a mainstay in textbooks, work on Lafora disease has 
yielded a number of recent breakthroughs regarding glycogen biology including the discovery of 
both glycogen dephosphorylation as well as putative therapies for glycogen storage diseases. 
Laforin is critical for regulating the phosphorylation state of glycogen, which is necessary to 
maintain glycogen homeostasis. Understanding the mechanism(s) underlying human disease 
mutations in laforin is critical for understanding the molecular basis for LD and normal glycogen 
metabolism. Herein, we report the structure of laforin bound to phospho-glucan product. The 
structure reveals the unique tertiary and quaternary architecture of laforin, providing a platform 
for understanding its causative role in LD. We define the basis for subsets of mutations that 
selectively disrupt laforin substrate engagement and specific activity. These data provide a key 
connection between this critical fundamental biological process and human neurodegenerative 
disease.   
 
RESULTS 
Crystal Structure of Laforin Bound to Maltohexaose 
 The structure of human laforin bound to maltohexaose and phosphate was determined 
using tungstate single-wavelength anomalous diffraction (SAD) phasing and refined to a 
resolution of 2.4 Å (Figure 1A and Table 1). There are two laforin molecules in the asymmetric 
unit, which are superimposable and each possesses a CBM and DSP domain. Laforin is the 
only known phosphatase in the human proteome that contains CBM and DSP domains, and the 
structure displays unique tertiary and quaternary structure. The N-terminal CBM domain is 
intimately associated with the DSP domain, forming an integrated tertiary structure. 
Furthermore, the two laforin molecules form an antiparallel dimer mediated entirely by the DSP 
domain (Figure 1A). Multiple maltohexaose molecules are bound to the laforin CBM and DSP 
domains, along with a single phosphate at the DSP active site. Maltohexaose is a soluble 
oligosaccharide composed of six glucose moieties with α-1,4-glycosidic linkages, and serves as 
a model for the linear portions of glycogen.  
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Laforin is the only known human phosphatase that can dephosphorylate glucan substrates 
(Gentry et al., 2007; Sherwood et al., 2013; Worby et al., 2006). To confirm the function of the 
crystallized laforin construct, we tested the ability of the catalytically active protein to both bind 
and dephosphorylate glycogen. Laforin readily bound to glycogen, whereas the prototypical 
human DSP protein phosphatase vaccinia H1-related (VHR/ DSP3) did not (Figure 1B).  
Additionally, laforin readily dephosphorylated glycogen (Figure 1C). This activity was specific, 
since mutation of the catalytic nucleophile (C266S) lacked specific activity. Additionally, VHR 
also lacked glycogen phosphatase activity. Thus, the crystallized laforin construct represents an 
active specific glycogen phosphatase. 
  This structure opens new avenues for understanding laforin function in glycogen 
dephosphorylation and the effect of LD disease mutations. A significant number of LD mutations 
are localized to regions of the protein involved in physical interactions, including the DSP active 
site, CBM binding site, CBM-DSP interface, buried regions within individual domains, and the 
DSP-DSP dimer interface. Thus, the laforin structure allows us to probe the mechanism(s) by 
which LD patient mutations affect laforin function. 
 
Maltohexaose and Phosphate Bound at the Laforin Active Site 
A bound maltohexaose chain and phosphate are tightly integrated into the laforin DSP 
domain active site, with a contact area of 655 Å2. The active site is broad, with a cross section 
~17 Å wide and 10 Å deep, and is formed by residues from different portions of the DSP domain 
whose variability among DSP family members yields unique substrate specificities (Figure 2A). 
The laforin DSP domain is structurally most similar to the plant glucan phosphatases LSF2 and 
SEX4, with an R.M.S.D. of 2.0 and 2.1Å (Figure S1), respectively. The electron density of 
maltohexaose in the laforin active site allows unambiguous assignment of glucan chain 
orientation, labeled Glc1-Glc6 from the nonreducing to reducing end (Figure 2B). Seven 
conserved laforin residues make extensive interactions with the maltohexaose glucose moieties 
(Figure 2B). M236 fully engages the concave surface of the maltohexaose chain. T142, Y146, 
T194, D197, R241, N267, and Y304 interact with the convex surface, which involves many 
hydrogen bonds as well as van der Waals interactions. Each of these interacting residues is 
strictly conserved in laforin vertebrate orthologs (Figure S2A). At the base of the active site is 
the PTP-loop Cx5R motif (HCNAGVGR, residues 265-272). The cysteine within this motif sits at 
the base of the catalytic cleft and functions as a nucleophile during catalysis. The O3 and O2 of 
Glc3 are positioned 2.7 Å and 3.8 Å from the phosphate, respectively, with the O6 at a distance 
of 7.7 Å pointed towards solvent (Figure S3).   
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 To investigate the role of these residues in laforin function, we generated alanine mutations 
of M236, T142, and D197. Additionally, we tested multiple LD mutations in the DSP domain that 
are localized to the DSP active site, including R171H and G240S (Figure 2B). We first tested 
the effect of these mutations on laforin stability and folding by measuring protein stability using 
differential scanning fluorimetry (DSF). None of the mutations showed a significant decrease in 
stability (Table S1). After establishing that the laforin point mutants did not destabilize the 
protein, we tested the mutants’ phosphatase activity against glycogen. In all cases, we found a 
significant decrease in specific activity, ranging from 69-95% decrease compared to wild-type 
(WT) (Figure 2C). M236A was the most deleterious to laforin activity, consistent with its 
observed extended interaction surface with the bound carbohydrate.  
 Since the laforin DSP independently engages a glucan chain, a loss of glucan phosphatase 
activity may indicate a decrease in glucan binding. To assess binding to glycogen, we incubated 
laforin with glycogen coupled to Concanavalin A (Con A) Agarose (GE Healthcare), washed the 
agarose beads, performed a low speed spin, and used Western analysis to determine if laforin 
was bound to glycogen in the pellet or remained in the supernatant. We found that the laforin 
DSP mutants pelleted with glycogen similarly to WT (Figure 2D). Thus, mutations in the DSP 
domain active site channel do not dramatically decrease glycogen binding, but specifically 
impact the ability of laforin to dephosphorylate glycogen. 
 
Laforin CBM-Glucan Interactions 
 A separate maltohexaose chain is bound to the canonical carbohydrate binding site in the 
laforin CBM domain (Figure 3A). Aromatic and hydrophilic residues within the CBM engage the 
maltohexaose, with a contact area of 327 Å2, via a network of stacking interactions and 
hydrophilic residues including the sidechains of W32, K87, W99, and D107 and backbone of 
G103. The tryptophan residues interact with one face of the glucose units. W32, K87, and W99 
are strictly conserved and D107 is highly conserved in all laforin orthologs (Figure S2B). 
To define the contribution of the CBM to laforin activity, we mutated K87 and W99 to 
alanine, as well as assessed the LD patient mutation W32G. W32G showed reduced stability 
with the Tm decreased by 5.1˚C, indicating that it contributes to protein stability (Table S1). 
Indeed, the structure identifies a number of key core hydrophobic residues including F5, Y86, 
and F88 that are mutated in LD and likely destabilize the protein. In contrast, we found the other 
mutant proteins had equivalent stability to WT protein. To determine how these mutations 
impact laforin binding to glycogen, we employed the Con A-glycogen experiment. We found that 
W32G was the most deleterious, being found entirely in the supernatant fraction. K87A and 
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W99A also exhibited decreased glycogen binding by ~40% (Figure 3B). The CBM mutations 
resulted in a 57-96% decrease in glycogen phosphatase activity (Figure 3C). Thus, LD and 
CBM mutations that affect CBM domain stability and/or direct glucan engagement lead to loss of 
enzymatic activity. These data indicate the importance of glycogen engagement by the CBM 
domain for laforin activity. 
 
Laforin Architecture and Dynamics 
While each domain is clearly important for laforin function, the structure reveals a unique 
tertiary architecture with tightly integrated CBM and DSP domains, with a contact area of 1154 
Å2. The relative orientation of the CBM and DSP domains is dramatically different than that 
observed in the plant glucan phosphatase SEX4 (Figure S1). Most strikingly, the two 
carbohydrate binding sites are not proximal, as was seen in SEX4 (Figure S1). Thus, we next 
probed the relationship and coupling between the protein domains.  
We employed deuterium exchange mass spectrometry (DXMS) to elucidate the 
conformational dynamics of laforin in solution, and the effect of binding to its physiological 
substrate glycogen in terms of changes in tertiary and quaternary structure. Optimization of the 
assay allowed 100% coverage of C-terminally His6-tagged laforin WT and allowed us to assess 
the change in peptide mass with increasing time (Figure S4A). Strong differences in protection 
were observed for different regions of the protein (Figure 4A and 4B). Among the most 
protected regions, defined as <20% deuteration from 10 s to 1,000 s, are residues 122-129 in 
the CBM domain and 290-296 in the DSP domain. These are residues in the complementary 
surfaces of the CBM-DSP domain interface, indicating that the observed tertiary structure is 
stable in solution and suggesting that there is minimal structural rearrangement of this region. 
Additionally, residues 218-227 and 252-256, both located at the dimer interface in the DSP 
domain, exhibit <20% deuteration throughout the experiment, consistent with stable dimer 
association in solution. 
Regions that are highly accessible to solvent, defined as greater than or equal to 50% 
deuterated after 300 s in D2O, are primarily within surface exposed regions (Figure 4B). The 
region that is the most highly solvent accessible, exhibiting >90% deuteration at all time points, 
is residues 66-84 of the CBM domain that corresponds to the disordered loop not modeled in 
the crystal structure (Figure 4A). The CBM-DSP domain linker and DSP recognition motif also 
displayed >70% deuteration at 300 s (Figure 4A and 4B) yet other peptides did not display high 
levels of deuteration, suggestive of local dynamics but not global conformational changes. 
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 Next, we utilized DXMS to evaluate structural changes in laforin in the presence of its 
endogenous substrate glycogen. In the presence of glycogen, we observed significant 
substrate-induced decreases in the exchange rate within both the CBM and DSP domain 
(Figures 4C and S4B). Three peptides within the CBM exhibited 13-27% decreases of 
deuteration in the presence of glycogen: residues 21-52, residues 60-65, and residues 98-111. 
The identified oligosaccharide-binding residues W32, W99, and D107 lie within these regions 
(Figure 4A). Likewise, regions within the DSP domain surrounding the active site also showed 
significant protection, decreases of 13-45%, including within the recognition domain (residues 
130-145, 146-155), V-loop (residues 193-217), D-loop (residues 228-236), PTP loop (267-281), 
and R-motif (308-317). Changes were restricted to the surface of the laforin structure 
encompassing the active site cleft with little to no change on the opposite face (Figure 4D). 
Peptides involved in the CBM-DSP domain interface and the dimerization interface did not 
exhibit significant changes in the presence of glycogen. Indeed, there were no significant 
increases in deuteration in any region of laforin, suggesting that there is not an increase in 
protein dynamics associated with substrate binding. Intriguingly, the CBM and DSP-bound 
maltohexaose chains are positioned in a parallel orientation, i.e. the non-reducing and reducing 
ends are oriented in the same direction. When residue conservation is mapped onto the surface 
of the structure, very high levels of conservation are observed for the active site and intervening 
region to the CBM binding site (Figure 4E). These regions closely resemble the less deuterated 
regions in the presence of glycogen, suggestive of a physical path for cooperative binding of 
glycogen. 
 
The CBM and DSP Domain Interaction is Critical for Function and Impacts Lafora Disease 
 Given the extensive interdomain interface, stable dynamics, and conservation we 
hypothesized that the observed CBM/DSP orientation exhibited in the laforin tertiary structure is 
critical for its function (Figure 5A). Indeed, many of the residues that participate in interdomain 
interactions are mutated in LD, including I126T, Q293L, Y294N, and P301L. We generated an 
alanine mutation of V8, as well as analyzed the LD mutants I126T, Y294N, and P301L, all of 
which are located at the interdomain interface. P301L displayed a decreased Tm, while all other 
mutant proteins were stable and well folded with no significant difference in Tm compared to WT 
protein (Table S1). We investigated the glycogen binding of these mutations using a Con A-
glycogen assay and found that each mutant pellets with glycogen, indicating that glycogen 
binding is not dramatically affected (Figure 5B). Next, we tested the glycogen phosphatase 
activity of each mutant and found that V8A, I126T, Y294N, and P301L significantly decreased 
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the glycogen phosphatase activity of laforin by 47-93% (Figure 5C). Thus, mutations within the 
CBM-DSP interface significantly decrease glycogen phosphatase activity without diminishing 
glycogen binding. 
 To further explore the structural dynamics of the CBM-DSP interface, we performed DXMS 
analysis of the LD patient mutation laforin Y294N. Strikingly, the Y294N mutation significantly 
increased the solvent accessibility of the CBM/DSP interface (Figures 5D, 5E and S4C). 
Specifically, residues 290-296 and 297-307 were 95% and 45% more deuterated in laforin 
Y294N than in WT, respectively. These residues surround Y294 and include the DSP domain 
residues that comprise the CBM-DSP interface (Figure 5E). Further, CBM domain residues 
comprising the opposite side of the interface also exhibit increased deuteration compared to WT 
with residues 113-121 and 122-129 increasing 50% and 39%, respectively. While the CBM/DSP 
interface exhibited increased deuteration, there was no significant change in deuteration of 
peptides comprising the dimer interface. These results indicate that the unique tertiary structure 
with specific CBM/DSP orientation is required for laforin activity and provides an explanation for 
the role that mutations of these interfacial residues play in LD. 
 
Laforin Dimerization 
 The physical and functional role of laforin oligomerization has been controversial (Dukhande 
et al., 2011; Koksal and Cingolani, 2011; Liu et al., 2006; Liu et al., 2009; Sanchez-Martin et al., 
2013). In situ and in vivo experiments have demonstrated that laforin is able to both dimerize 
and multimerize, but different models have been proposed for the extent to which oligomers 
form and which domains contribute. The structure reveals that laforin is an anti-parallel dimer 
mediated exclusively by the DSP domains, with an extended 906 Å2 interface and high shape 
complementarity (Sc=0.81) (Figure 1A).  
To examine the structure of laforin in solution, we employed inline size exclusion 
chromatography-small angle X-ray scattering (SEC-SAXS). Laforin eluted from SEC as a single 
species (Figure S5A) with molecular size and shape parameters Rg = 33.9 ± 0.2 Å and Dmax = 
119 Å. Rg was invariant across a twenty five-fold concentration range as the protein eluted from 
the column (33.7 ± 0.7 Å for the entire range) indicating that the protein was not exchanging 
between oligomeric states. The experimental scattering curve demonstrated strong agreement 
with the theoretical profile calculated for the laforin dimer (predicted Rg = 31.2 Å and Dmax = 121 
Å) observed in the crystal structure (χ2 = 1.1) (Figures 6A, S5B, and S5C). In contrast, the 
theoretical scattering profile for a single copy of laforin monomer (predicted Rg = 21.2 Å and 
Dmax = 78 Å) showed a marked deviation from the experimental data (χ2 = 27.0). An ab initio 
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reconstruction of the average molecular envelope revealed an extended bilobal shape that 
closely matched the crystal structure of laforin (Figure 6B). The excluded volume indicated that 
the molecular weight of the protein was 72 kDa, matching the theoretical molecular weight of the 
laforin dimer (74 kDa) and further confirming that laforin forms a stable dimer in solution. Thus, 
the solution scattering data demonstrate that the tertiary and quaternary structure of laforin 
observed in the crystal structure represent the native conformation of the protein in solution. 
 Closer examination of the dimerization interface demonstrates that it contains a core 
hydrophobic region comprised of I229, M231, L251, C250, and F321 and outer hydrophilic 
regions containing D215, R222, E239, Q243, and K320 (Figure 6C). In particular, F321 is 
buried at the interface and is mutated in the LD patient mutation F321S. 
 To determine the effect of mutations at the laforin dimeric interface on function we next 
tested the effect of F321S or L251A mutations. Both mutations significantly affected laforin 
stability, resulting in >5ºC decreases in protein stability (Table S1). Mutation at the dimer 
interface also significantly decreased glycogen phosphatase activity, with observed activity 
decreases of 56-62%, but without global effects on glycogen binding (Figure 6D and 6E).  
 
Laforin Substrate Binding Cooperativity 
To examine the oligomeric state of the F321S LD mutation, we employed analytical 
ultracentrifugation (AU). Consistent with SEC and SAXS solution measurements, WT laforin 
exists as a stable dimer in solution with a single peak observed at 79 ± 6 kDa (Figure 7A and 
S6A). Strikingly, the F321S mutation disrupts dimerization, existing as a single species of 41 ± 6 
kDa, consistent with the monomeric molecular weight of laforin (Figure 7B, S6B).  
 The dimeric form of laforin is structurally organized with CBM binding interfaces and DSP 
active sites aligned. We next tested the role of dimerization in substrate binding by measuring 
the binding of laforin to varying lengths of oligosaccharides using a thermal shift assay. We first 
tested the degree of stabilization in the presence of malto-oligosaccharides from maltose of 
degree of polymerization 2 (DP2) through DP24. We saw little effect with DP2-DP4 
oligosaccharides and a minimal length-dependent increase in Tm for DP5-DP8 with each 
additional glucose moiety yielding an ~0.3˚C ∆Tm (Figure 7C). Strikingly, there was a dramatic 
increase in stabilization when using longer oligosaccharides, with a 24-mer yielding a ∆Tm 
increase of ~14˚C. Further, when the concentration dependence was measured, a shorter 
oligosaccharide showed a broad transition with two binding events, whereas the longer 
oligosaccharide showed a single high affinity binding with a Hill coefficient of 1.41, 
demonstrating striking cooperativity in binding (Figure 7D). We next assessed the effect of 
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laforin mutant protein for cooperative binding. F321S exhibited a significantly decreased degree 
of stabilization by glucan substrate and notably loss of cooperativity, with a Hill coefficient of 
0.95 (Figure 7E). Overall, these data provide a mechanism for laforin dimerization in its 
function, and provide a basis for understanding the effect of LD mutations that disrupt 
dimerization.  
 
DISCUSSION 
 The role of glycogen dephosphorylation is an emerging area of research that directly 
impacts our understanding of normal glycogen metabolism as well as dysfunction in the fatal 
human epilepsy Lafora disease. The data presented here provide fundamental insights into how 
laforin functions in glycogen dephosphorylation and uncovers novel features of the laforin 
protein that provide a basis to understand disease mechanisms. The domain orientation in 
laforin is unique and distinct from the other known glucan phosphatases with the carbohydrate 
binding regions of the CBM and DSP domains distant from each other. In contrast, SEX4 
employs a continuous binding pocket that spans both the CBM binding site and DSP active site 
allowing it to bind a single maltohexaose chain (Meekins et al., 2014). The laforin dimer 
produces a unique tetramodular architecture with CBM-DSP-DSP-CBM domains aligned and 
engaging multiple maltohexaose chains. Structure-guided and patient mutations are described 
that result in loss of functional interactions in the CBM binding site, DSP active site, CBM/DSP 
interface, and dimerization interface. Our data demonstrate that this unique tertiary and 
quaternary structure allows for engagement of glycogen by the CBM domain, cooperative 
substrate binding by the dimer, engagement of the phosphorylated glucan at the DSP active 
site, and finally catalysis.  
This model has direct implications for our understanding of the source and position-specific 
function of glycogen phosphorylation on both glycogen superstructure and LB formation, which 
is currently being explored. Some propose that phosphate is introduced by a glycogen synthase 
side reaction, while others suggest specific incorporation by a yet unidentified human glycogen 
kinase (Nitschke et al., 2013; Tagliabracci et al., 2011). In plants, regulated phosphorylation of 
starch is better characterized. Glucan, water dikinase (GWD) specifically phosphorylates the C6 
position that targets phosphoglucan, water dikinase (PWD) to phosphorylate C3 hydroxyls. 
These phosphorylation events induce steric strain and disrupt the helical structure of starch, and 
allow hydrolytic enzymes to processively degrade starch (Blennow and Engelsen, 2010; Silver 
et al., 2014; Streb and Zeeman, 2012). Complementary to the dikinases, the plant glucan 
phosphatases possess distinct preference for dephosphorylating glucose positions. SEX4 
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preferentially dephosphorylates the C6 position, while LSF2 exclusively dephosphorylates the 
C3 position (Kotting et al., 2009; Meekins et al., 2013; Meekins et al., 2014; Santelia et al., 
2011). This position-specific activity was shown to be due to orientation-specific binding of the 
glucan substrates in the active site with C3-hydroxyls in the active site of LSF2 and C6-hydroxls 
for SEX4 (Meekins et al., 2013; Meekins et al., 2014). Glycogen can be phosphorylated at the 
C2, C3, and C6 position (Nitschke et al., 2013). The laforin structure shows preferential binding 
of the glucan with C3/C2 oriented towards the catalytic center, suggesting that it will 
preferentially dephosphorylate C3 or C2 positions (Figure S3). Indeed, the C6 hydroxyls are 
pointed away from the laforin active site into the solvent. As with SEX4, laforin likely will be able 
to act on all positions to some extent, but would require the opposite glucan orientation to 
accommodate dephosphorylation of the C6 position and thus is expected to have significantly 
reduced activity level for the C6 position.   
Currently, the position of phosphorylation with respect to α-1,6 branchpoints is unresolved. It 
has been reported that C6 monophosphates may be selectively elevated in LBs and 
predominate near the center of glycogen molecules, thereby affecting branching (Nitschke et al., 
2013). Intriguingly, an additional portion of an oligosaccharide chain is observed in the crystal 
structure of laforin near the DSP active site and a single ordered glucose moiety is observed 
near the CBM binding site. This is likely a consequence of the high concentration of 
carbohydrate used in crystallization, but it may suggest the possibility of preferential binding to 
specific glycogen regions, particularly branch points. The laforin structure demonstrates that a 
shallow and wide binding pocket (10 Å x 17 Å) is a conserved feature of glucan phosphatases 
from plants to animals and an architectural feature that would accommodate a branched 
glycogen chain. The ability of laforin to bind and localize to specific sub-regions within glycogen 
is an area of on-going research that will require temporal and quantitative comparisons of wild 
type and mutant proteins in the context of physiological substrates. These results will further 
define the role of phosphorylation/ dephosphorylation in LB formation and disease progression. 
 The physical and physiological relevance of laforin dimerization has been a point of debate 
in the field (Dukhande et al., 2011; Liu et al., 2006; Liu et al., 2009; Sanchez-Martin et al., 
2013). The crystal structure, along with solution-based measurements using complementary 
techniques, establishes that laforin exists as an antiparallel dimer mediated by the DSP domain. 
Notably, laforin does not possess a CT-motif, which is required for stability and function in plant 
glucan phosphatases. Instead, the laforin dimer interface partially overlaps with the region 
where the CT-motif binds to the DSP domain (Figure S1). Furthermore, we demonstrate that 
the LD mutation F321S disrupts laforin dimerization and diminishes glycogen phosphatase 
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activity and cooperative substrate binding. Dimerization is a common theme regulating the 
activity of transmembrane receptor-like PTPs (RPTPs). A helix-turn-helix wedge motif of one 
RPTP obstructs the active site of the dimer partner, possibly allowing a ligand-dependent 
manner to modulate phosphatase activity (Tonks, 2006, 2013). Conversely, dimerization of 
cytoplasmic PTPs is much less common and DSPs are typically regarded as monomeric 
enzymes. The human phosphoinositide lipid phosphatase myotubularin related protein 2 
(MTMR2) and the Vaccinia virus gene H1 (VH1) are both DSPs that dimerize. The laforin DSP 
domain forms its dimer interface, while both MTMR2 and VH1 form dimers via ancillary 
domains. MTMR2 forms a dimer via its C-terminal coiled-coil domain, while the VH1 dimer 
interface is formed by a swapped N-terminal α-helix (Berger et al., 2003; Koksal and Cingolani, 
2011; Phan et al., 2007).  
 LD offers a unique window into both normal cellular glycogen metabolism and disease 
implications when the process is perturbed. Recently, a study using a novel glycogen detection 
method demonstrated that neurons contain low levels of glycogen, and this glycogen protects 
neurons from hypoxic stress in vitro and in vivo (Saez et al., 2014). Yet, glycogen synthesis in 
neurons must be tightly controlled, because over-accumulation induces neuronal apoptosis 
(Duran et al., 2014; Valles-Ortega et al., 2011; Vilchez et al., 2007). Intriguingly, insoluble 
starch-like accumulations also accumulate in neurons during human aging. Corpora amylacea 
are insoluble, glucan-based aggregates that form in brain, eye, and peripheral nervous system 
neurons of individuals thirty years old and greater (Cavanagh, 1999; Sinadinos et al., 2014). 
The function of corpora amylacea as well as their impact on cellular homeostasis and 
involvement of laforin is unknown, yet recent evidence suggests that corpora amylacea may 
constitute an important factor in age-related neurological decline (Sinadinos et al., 2014).  
In addition to impacting neuronal processes, perturbations in glycogen metabolism are a 
feature of glycogen storage diseases, diabetes, cardiac pre-excitation syndromes, and cancer 
(Light, 2006; Roach, 2002; Roach et al., 2012; Ros and Schulze, 2012). Given the central 
importance of glycogen to cellular homeostasis, glycogen (de)phosphorylation may impact other 
aspects of human disease that are yet unexplored. The role of regulated carbohydrate 
phosphorylation in diverse biological systems by glucan phosphatases, glucan dikinases, and 
yet to be discovered enzymes opens new avenues for understanding novel aspects of glycogen 
metabolism as well as human diseases. 
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EXPERIMENTAL PROCEDURES 
 
Please refer to Supplemental Experimental Procedures for additional experimental details. 
 
Cloning, Protein Expression, and Protein Purification 
H. sapiens (Hs) laforin residues 1-328 was expressed from pET28b (Novagen) as an N-terminal 
His6 tag fusion. Wild-type and mutant proteins were expressed in BL21-CodonPlus E. coli cells 
and purified using IMAC and SEC.  
 
Crystal Structure Determination 
High quality single native and tungstate co-crystals were obtained and data collected on the 22-
ID beamline of SER-CAT at the Advanced Photon Source, Argonne National Laboratory to 2.4 
Å and 3.0 Å, respectively (Table 1).  
 
Phosphatase Assays 
We utilized a phosphatase assay that employs malachite green to quantify inorganic phosphate 
release from rabbit muscle glycogen, assays were performed six times or more (Sherwood et 
al., 2013; Tagliabracci et al., 2008; Tagliabracci et al., 2007). 
 
Glycogen Binding Assays 
Glycogen binding assays were performed using Concanavalin A (Con A) Agarose beads 
(Sigma) as described in Supplemental Experimental Procedures. 
 
Hydrogen Deuterium Exchange Mass Spectrometry (DXMS) 
DXMS experiments were performed as previously described (Hsu et al., 2009; Pantazatos et al., 
2004). 134 high-quality peptides with 100% coverage of laforin were obtained. Exchange of 
laforin with and without glycogen was performed three independent times, with all samples 
prepared in triplicate.  
 
Size-Exclusion Chromatography Small - Angle X-ray Scattering (SEC-SAXS) 
SEC-SAXS experiments were performed at the 18-ID beamline of BioCAT, Advanced Photon 
Source, Argonne National Laboratory using an inline Superdex 75 10/300 column (GE). Guinier 
analysis demonstrated that the system is monodisperse with particles that have a radius of 
gyration (Rg) = 33.9 ± 0.2 Å (Figure S5B). Pair-distance distribution function (P(r)) 
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demonstrated a well-defined Dmax = 119 Å and real space Rg (35.0 Å) consistent with Guinier 
analysis (Figure S5C).  
 
Analytical Ultracentrifugation (AU) 
Sedimentation velocity experiments were conducted using a Beckman XL-I analytical 
ultracentrifuge (Beckman-Coulter, Fullerton, CA). Protein was concentrated to 5 µM in size 
exclusion buffer.  
 
Differential Scanning Fluorimetry (DSF) 
Thermal stability experiments were carried out using a CFX96 Real-Time PCR system 
(BioRad). 2 µM of protein was combined with 5X SYPRO Orange Protein Gel Stain (Invitrogen) 
with or without maltoligosaccharides and stability assessed from 20 to 90 ˚C at 1 ˚C/50 s in 
triplicate.  
 
ACCESSION NUMBERS 
The atomic coordinates and structure factors are available in the Protein Data Bank deposited 
with the PDB code 4RKK. 
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Supplemental Information includes Supplemental Experimental Procedures, six figures, and one 
table and can be found with this article online. 
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FIGURE LEGENDS 
 
 
Figure 1. Crystal structure of human laforin bound to maltohexaose and phosphate 
(A) Structure of human laforin bound to maltohexaose (green) and phosphate (orange). The 
laforin structure is an anti-parallel dimer with one molecule in blue and the other in red. Each 
molecule contains a CBM and DSP domain yielding a tetramodular CBM1-DSP1-DSP2-CBM2 
structure. Maltohexaose chains are bound at the CBM and DSP domains with a single 
phosphate molecule located at the base of the catalytic site. 
(B) Glycogen co-sedimentation assay to measure glycogen binding. Recombinant laforin wild-
type (WT), laforin C266S, and VHR were incubated with glycogen bound to Con A agarose 
beads, glycogen was pelleted by centrifugation, and proteins in the pellet (P) and supernatant 
(S) were separated by SDS-PAGE and visualized by Western analysis. Glycogen-bound 
proteins are in the pellet and unbound proteins are in the supernatant.  
(C) Specific activity of laforin WT, inactive mutant laforin C266S, and human VHR against 
glycogen. 100 ng of protein was incubated with 45 µg glycogen for 20 minutes. Each bar is the 
mean ± SEM of six replicates, P < 0.05. 
 
Figure 2. Maltohexaose bound at the laforin DSP domain active site. 
(A) Ribbon diagram of one laforin molecule with maltohexaose (green), phosphate (orange), 
backbone (grey), DSP domain motifs (blue), active site loop (red), and the second molecule 
(light grey).  
(B) Inset from A, showing a 2Fo-Fc electron density map (1.3 σ) with maltohexaose (green) and 
phosphate (orange). Glucose moieties (Glc) are numbered from non-reducing to reducing end. 
Side chains of interacting residues are colored yellow. See also Figure S3. 
(C) Specific activity of laforin WT and C266S (from Figure 1) compared to DSP active site 
mutants. Each bar is the mean ± SEM of six replicates, P < 0.05. 
(D) Glycogen co-sedimentation assay of WT and DSP active site mutants. 
 
Figure 3. Maltohexaose bound at the laforin CBM domain. 
(A) Close-up of the laforin CBM domain with bound maltohexaose (green) 2Fo-Fc electron 
density map (1.0 σ) with CBM residues (yellow). Glucose moieties (Glc) are numbered from 
nonreducing to reducing end.  
(B) Glycogen co-sedimentation assay of WT and CBM domain mutants. 
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(C) Specific activity of laforin WT and C266S (from Figure 1) compared to CBM domain 
mutants. Each bar is the mean ± SEM of six replicates, P < 0.05.  
 
Figure 4. Deuterium exchange mass spectrometry (DXMS) analysis of laforin 
architectural dynamics. 
(A) Laforin dynamics from DXMS expressed as percent deuteration of laforin peptides with the 
lowest deuteration in blue to highest in red, as indicated. Each colored bar below the primary 
sequence represents percent deuteration at one of seven timepoints. Secondary structure 
elements are depicted above the primary sequence with the CBM domain and DSP motifs 
labeled.  
(B) Surface mapping of the percent deuterium exchange of each peptide at 300 s was mapped 
onto the laforin structure. Residues 69-79 were 100% deuterated throughout the DXMS 
experiment, and these residues were disordered and not modeled in the structure (labeled 
disordered loop). 
(C) Maximal percent change in deuteration of laforin ± glycogen versus the laforin primary 
sequence. The dotted line designates 10% decrease. See also Figure S4B. 
(D) Surface mapping depicting the regions that exhibit decreased deuteration in the presence of 
glycogen.  
(E) Surface model of laforin illustrating amino acid conservation using the sequences from 
Figure S2A and S2B.  
 
Figure 5. The laforin CBM-DSP interface is necessary for laforin function. 
(A) Close up of the CBM (light blue) DSP (dark blue) domain interface. Residues that comprise 
the CBM-DSP interface are yellow. 
(B) Glycogen co-sedimentation assay of WT and CBM-DSP interface mutants. 
(C) Specific activity of laforin WT and C266S (from Figure 1) compared to CBM-DSP interface 
mutants. Each bar is the mean ± SEM of six replicates, P < 0.05. 
(D) Structural dynamics of the laforin mutant Y294N with a bar graph depicts maximal percent 
change in deuteration between WT and Y294N, positive values depict increased deuteration in 
Y294N and negative values depict decreases. The dotted line designates 30% change in 
deuteration.  
(E) Surface mapping of regions that exhibit changes deuteration between WT and Y294N.  
 
Figure 6. Laforin quaternary structure is critical for its function. 
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(A) Scattering curve of laforin C266S (black) with curves computed from the crystallographic 
structure for monomer (red) and dimer (green).  
(B) Ab initio model of laforin C266S with the computed surface (gray mesh) overlayed with the 
crystal structure. 
(C) The laforin DSP domain dimer interface with interfacial hydrophilic (green) and hydrophobic 
interacting residues (gold). Residues from DSP1 are labeled. 
(D) Specific activity of WT and C266S (from Figure 1) compared to dimer interface mutants. 
Each bar is the mean ± SEM of six replicates, P < 0.05.  
(E) Glycogen co-sedimentation assay of WT and dimer interface mutants. 
 
Figure 7. Cooperative binding to glucan substrates. 
(A) Sedimentation velocity experiments reveal that laforin WT exists as a dimer in solution. 
(B) Sedimentation velocity experiments reveal that laforin F321S exists primarily as a monomer 
in solution. 
(C) Thermal shift assay with 1 mM oligosaccharides reveals that laforin C266S is more 
stabilized in the presence of increasing degree of polymerization (DP).  
(D) Concentration dependent increase in laforin C266S melting temperature (∆Tm) with 
maltohexaose (DP6) maltodextrin (DP24). 
(E) Concentration dependent increase in laforin F321S melting temperature (∆Tm) with 
maltohexaose (DP6) maltodextrin (DP24). 
 	  	  	  	  
